RHJA
VNDA icon

Rice Hall James & Associates’s Vanda Pharmaceuticals VNDA Stock Holding History

Rice Hall James & Associates’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-60,309
Closed -$990K – 285
2019
Q4 		$990K Sell
60,309
-233
-0.4% -$3.52K 0.03% 233
2019
Q3 		$804K Buy
60,542
+1,615
+3% +$22.5K 0.03% 235
2019
Q2 		$830K Buy
58,927
+3,017
+5% +$48K 0.03% 243
2019
Q1 		$1.03M Buy
55,910
+17,646
+46% +$402K 0.03% 247
2018
Q4 		$1M Buy
38,264
+13,649
+55% +$321K 0.04% 246
2018
Q3 		$565K Sell
24,615
-108
-0.4% -$2.21K 0.02% 267
2018
Q2 		$471K Buy
24,723
+421
+2% +$7.04K 0.02% 270
2018
Q1 		$409K Sell
24,302
-3,943
-14% -$66K 0.02% 271
2017
Q4 		$429K Buy
28,245
+323
+1% +$4.79K 0.02% 277
2017
Q3 		$500K Buy
27,922
+19
+0.1% +$318 0.02% 263
2017
Q2 		$455K Buy
27,903
+279
+1% +$4.02K 0.02% 262
2017
Q1 		$387K Buy
27,624
+739
+3% +$10.5K 0.02% 276
2016
Q4 		$429K Buy
26,885
+4,542
+20% +$73K 0.02% 269
2016
Q3 		$372K Buy
22,343
+274
+1% +$3.69K 0.02% 271
2016
Q2 		$247K Sell
22,069
-188
-0.8% -$1.82K 0.01% 283
2016
Q1 		$186K Sell
22,257
-340
-2% -$2.79K 0.01% 290
2015
Q4 		$210K Buy
22,597
+631
+3% +$6.3K 0.01% 294
2015
Q3 		$248K Sell
21,966
-995
-4% -$12.2K 0.02% 287
2015
Q2 		$291K Sell
22,961
-2,408
-9% -$26K 0.02% 289
2015
Q1 		$236K Buy
25,369
+655
+3% +$7.4K 0.01% 302
2014
Q4 		$354K Buy
24,714
+357
+1% +$4.22K 0.02% 284
2014
Q3 		$253K Buy
24,357
+303
+1% +$3.97K 0.02% 282
2014
Q2 		$389K Buy
24,054
+350
+1% +$4.66K 0.03% 274
2014
Q1 		$385K Buy
+23,704
New +$337K 0.03% 274

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Rice Hall James & Associates's VNDA Position: Q1 2020 in Review

Rice Hall James & Associates sold out of Vanda Pharmaceuticals (VNDA) in Q1 2020, closing a stake of 60,309 shares — an estimated $990K sold.

Rice Hall James & Associates first reported a position in VNDA in Q1 2014 and held it in 24 quarters. The position peaked at $1.03M in Q1 2019. 159 funds tracked by Wall St. Rank hold VNDA as of Q1 2020.

  • Rice Hall James & Associates reported no remaining Vanda Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Rice Hall James & Associates sold 60,309 Vanda Pharmaceuticals shares in Q1 2020, an estimated $990K.
  • Rice Hall James & Associates first reported a position in Vanda Pharmaceuticals in Q1 2014 and held it in 24 quarters.
  • Rice Hall James & Associates's Vanda Pharmaceuticals position peaked at $1.03M in Q1 2019.
  • 159 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2020.

Based on Rice Hall James & Associates's 13F filing for Q1 2020, filed 15 May 2020.